Skip to main content
Premium Trial:

Request an Annual Quote

European Collaboration Launches Effort to Develop Lab-on-Chip for Cancer Dx

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – A European research team launched a new project this week that's aimed at developing lab-on-chip technology for detecting cancer cells in blood.

The project, known as the "Magnetic Isolation and Molecular Analysis of Single Circulating and Disseminated Tumor Cells on Chips," or MIRACLE, is being coordinated at Europe's Interuniversity Microelectronics Centre. Together, it includes participants from 14 European research institutions and companies. MIRACLE is largely funded through the European Commission's Seventh Framework program.

Those involved in the effort intend to develop lab-on-chip technology that can be used to track down circulating tumor cells and disseminated tumor cells in blood samples and other clinical samples — a strategy they say would offer a quick and inexpensive approach for diagnosing cancer, gauging metastasis risk, and following individuals during and after cancer treatment.

The group announced the project at the Engineering in Medicine and Biology Conference in Buenos Aires this week.

In addition to Interuniversity Microelectronics Centre, participants include Universitat Rovira I Virgili (Spain); the Institut für Mikrotechnik Mainz, AdnaGen, ThinXXs, and Consultech (Germany); MRC Holland (The Netherlands); the Oslo University Hospital (Norway); the KTH Royal Institute of Technology, Multi-D, and Fujirebio Diagnostics (Sweden); ECCO - the European CanCer Organisation and ICsense (Belgium); and Labman (UK).

Some members of the collaboration participated in previous projects focused on coming up with microfluidic modules for use in related processes, ranging from cell isolation and cell counting to DNA amplification and detection.

For the MIRACLE project, the team intends to build on such past work, bringing together researchers specialized in microfluidics, miniaturization, and other fields to create a lab-on-chip platform that is not only automated but also has integrated circulating tumor cell isolating, counting, and genotyping capabilities.

For instance, the researchers reportedly hope to create a system that can be used to test messenger RNA extracted from cells in the blood for specific cancer markers using multiplex ligation dependent probe amplification combined with electrochemical sensors.

The MIRACLE project is the latest in a series of efforts focused on developing lab-on-chip technology for research and clinical purposes.

Earlier this week, GenomeWeb Daily News reported that the San Diego-based microfluidics company Biocept is pursuing its own lab-on-chip technology for use in diagnostic testing based on circulating tumor cell detection.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.